Head and Neck Cancers

Latest News

conceptual image of head and neck against yellow background
Stopping ICIs at 1 or 2 Years May Not Compromise Survival in HNSCC

September 11th 2024

This retrospective, population-based study shows strong efficacy across multiple patient subgroups and different lines of therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Patients With Postoperative Delirium May Benefit From a Holistic Management Approach
Patients With Postoperative Delirium May Benefit From a Holistic Management Approach

August 18th 2024

Adding Pembrolizumab to Chemo Demonstrates Antitumor Activity in Head and Neck Squamous Cell Carcinoma
Adding Pembrolizumab to Chemo Demonstrates Antitumor Activity in Head and Neck Squamous Cell Carcinoma

August 12th 2024

Ozuriftamab Vedotin Receives Fast Track Designation for Recurrent/Metastatic HNSCC
Ozuriftamab Vedotin Receives Fast Track Designation for Recurrent/Metastatic HNSCC

August 9th 2024

Cisplatin-Based Chemotherapy May Affect Hearing in Cancer Survivors
Cisplatin-Based Chemotherapy May Affect Hearing in Cancer Survivors

July 22nd 2024

Video Interviews
Podcasts
Latest CME Events & Activities

Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease

View More

Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition

December 6, 2024

Register Now!

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

View More

The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…

View More

18th Annual New York GU Cancers Congress™

March 28-29, 2025

Register Now!

Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

26th Annual International Lung Cancer Congress®

July 25-26, 2025

Register Now!

More News

© 2024 MJH Life Sciences

All rights reserved.